Lyra Therapeutics (LYRA) Other Gross PP&E Adjustments (2021 - 2025)
Historic Other Gross PP&E Adjustments for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$12.0 million.
- Lyra Therapeutics' Other Gross PP&E Adjustments rose 1980.63% to -$12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.0 million, marking a year-over-year increase of 1980.63%. This contributed to the annual value of -$15.5 million for FY2024, which is 4916.94% up from last year.
- Per Lyra Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at -$12.0 million for Q3 2025, which was up 1980.63% from -$12.9 million recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Other Gross PP&E Adjustments ranged from a high of $7.0 million in Q2 2022 and a low of -$45.6 million during Q1 2024
- For the 5-year period, Lyra Therapeutics' Other Gross PP&E Adjustments averaged around -$6.6 million, with its median value being -$1.8 million (2023).
- As far as peak fluctuations go, Lyra Therapeutics' Other Gross PP&E Adjustments surged by 9188.42% in 2022, and later crashed by 240005.48% in 2024.
- Lyra Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at $6.2 million in 2021, then crashed by 53.08% to $2.9 million in 2022, then tumbled by 1148.67% to -$30.4 million in 2023, then soared by 49.17% to -$15.5 million in 2024, then grew by 22.31% to -$12.0 million in 2025.
- Its Other Gross PP&E Adjustments stands at -$12.0 million for Q3 2025, versus -$12.9 million for Q2 2025 and -$13.6 million for Q1 2025.